<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618293</url>
  </required_header>
  <id_info>
    <org_study_id>BI8021_5101</org_study_id>
    <nct_id>NCT00618293</nct_id>
  </id_info>
  <brief_title>Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis</brief_title>
  <acronym>HAVAS</acronym>
  <official_title>Phase 2 Study in Evaluation of the Efficacy and Safety of Haemate HS in This Clinical Setting (Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of efficacy by determination of transfusion requirements and safety by
      determination of adverse events in administration of Von Willebrand factor concentrate F VIII
      (Haemate).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient met the criteria for inclusion in the study.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intra- and postoperative transfusion requirements of packed red cells, platelet concentrates and fresh frozen plasma according to defined transfusion thresholds</measure>
    <time_frame>begin of surgery and 48h after administration of medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events and viral safety</measure>
    <time_frame>1.perioperative 2. during hospital admission 3. within 90 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous infusion of Haemate (dosage dependent on body weight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous infusion of 0.9% NaCl solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haemate HS</intervention_name>
    <description>intravenous infusion of Haemate (dosage dependent on body weight)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl-solution</intervention_name>
    <description>intravenous infusion of 0.9%NaCl-Solution</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with isolated valvular aortic stenosis or combined aortic-valve defect with
             prevailing stenosis with severe bleeding during aortic-valve replacement

          -  Caucasian

          -  written informed consent (Classification of bleeding as &quot;normal&quot;, &quot;moderate&quot; or
             &quot;excessive&quot; by the surgeon.Classification as excessive leads to recruitment)

        Exclusion Criteria:

          -  active endocarditis

          -  history suggestive for inherited oe acquired bleeding disorder

          -  concomitant coronary heart disease

          -  agents impairing platelet function up to 14 days before surgery

          -  Pregnancy

          -  inherited platelet function

          -  known intolerance against HAEMATE HS

          -  previous thromboembolic complications

          -  Hepatitis B, C or HIV infection

          -  previous chemotherapy

          -  emergency surgery within the last 7 days

          -  weight &lt; 50 kg and &gt; 100 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Feindt, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Kardiovaskuläre Chirurgie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Kardiovaskuläre Chirurgie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <name_title>Heinrich-Heine University, represented by Principal investigator Prof. Feindt</name_title>
    <organization>Department of Hemostasis and Transfusion Medicine</organization>
  </responsible_party>
  <keyword>intraoperative bleeding</keyword>
  <keyword>aortic-valve replacement</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>Von Willebrand</keyword>
  <keyword>HEAMATE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

